GlaxoSmithKline Launches $50M Biotech Venture Fund
U.K. pharmaceutical giant GlaxoSmithKline has launched a $50 million bioelectric medicine and technology venture capital fund to provide seed capital to the industry and will make its first investment in a...To view the full article, register now.
Already a subscriber? Click here to view full article